The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...

Per Roche, the approval makes Tecentriq Hybreza the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy in the ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Roche is hoping its Tecentriq will be the first immunotherapy approved in tough-to-treat breast cancer, after it stayed the spread of "triple negative" disease in a phase 3 trial. When combined ...

Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo ...

Roche’s cancer immunotherapy Tecentriq has produced strong results which could give it the lead in a key lung cancer indication. The drug reduced the risk of disease worsening or death when ...

16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

The U.S. approval of Roche's TECENTRIQ HYBREZA with ENHANZE represents the availability of the first and only subcutaneous anti- PD-L1 cancer immunotherapy. Approval was granted for all of the ...

announced Thursday an agreement with Roche Group (RHHBY.PK) to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab, the current standard of ...

Swiss pharmaceutical giant Roche said Wednesday that it was increasing its capacity to produce diagnostic tests to detect mpox, amid a flare-up of the potentially deadly virus. "We've ramped up ...